Syncromune, a Fort Lauderdale-based biotech, raises $100M Series A for cancer therapies
Summary
Syncromune, a Fort Lauderdale-based biotech startup on a mission to develop first in class immunotherapies for solid tumors in the oncology field, has raised a $100 million Series A.The round was led by an undisclosed new institutional investor and included existing backer Wasatch Equity Partners, a spokesperson for the company told Endpoints, which reported the news. In total, the company has raised $130 million, according to Pitchbook.Part of a new generation of vaccine-like approaches to the oncology field, Syncromune is working on an experimental procedure that freezes a tumor and then blasts it with a cocktail of multiple immunotherapies. There is a large unmet need because currently most metastatic solid tumor cancers are incurable, the company says.Syncromunes funding round is one of the largest in South Florida this year, and one of two mega-rounds in the healthcare field. In June, Insightec, a Miami-based healthcare technology seeking to revolutionize patient care with focused ultrasound, announced it has raised $150 million in equity financing, led by Fidelity Management & Research Company, Nexus Neurotech Ventures and Ally Bridge Group.Healthcare startups make up one of the largest sectors in South Florida venture capital. MinusSugar raises $2.5M to shake up the juice industry with sugar removal breakthrough Healthtech startup Definition Health sets sights on Miami to streamline surgery care with AI Special Report: Meet the startups shaping the future of healthcare, from Miami to the world